Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Latest Stories

Recently ASX-listed Blinklab claims the world’s best mobile phone app for detecting autism, the New Criterion’s Tim Boreham reports

May 20 2024

ARB Corp’s third-quarter performance showcased why shares continue to trade at a premium to the Small Industrials Index

May 16 2024


Following a strong run over the last year, brokers see further upside for shares of FleetPartners following first half results

May 15 2024

Life360 has doubled in share price since its March earnings result, but brokers believe further re-rating is still on the cards

May 14 2024


Previous Stories

Dr Boreham’s Crucible: Invion

May 13 2024

As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission


SiteMinder Travelling Well

May 01 2024

SiteMinder’s March quarter update showed the company is on track to reach positive earnings and cash flow next quarter and new product launches offer growth


Dr Boreham’s Crucible: 4D Medical

Apr 23 2024

The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA


Dr Boreham’s Crucible: Race Oncology

Apr 09 2024

Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports


And Now For Something Different: Royalties

Apr 02 2024

The New Criterion’s Tim Boreham explains the benefits of royalties and where to access them via the ASX


Dr Boreham’s Crucible: Hydrix

Mar 26 2024

Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX


Life360 Growth Outlook Boosted By Advertising

Mar 20 2024

Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations


Capitol Health’s Higher Margin Outlook

Mar 13 2024

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control


Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked


Dicker Data Still PC

Mar 07 2024

Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook



Analyse The Market From A Different Angle